← Leaderboards
Dwight H. Owen
Ohio State University
$1,210,636
Attributed
$3,977,773
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,977,773 · 3
By mechanism
R01$3,113,004 · 1
R25$630,020 · 1
R21$234,749 · 1
Top collaborators
- Christopher C. Coss4 shared
- Thomas A Mace4 shared
- Mitch A Phelps4 shared
- Claire F Verschraegen2 shared
- Xiaopei Huang1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- David P Carbone$20,647,321
- Kerry Anne Rogers$1,321,382
- Mitch A Phelps$6,387,631
- Lapo Alinari$4,506,413
Others in their field
Other Rising Stars on “Malignant Neoplasms”
- David Annett · Information Management Services, Inc.$35,571,865
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Jon White · Midwest Research Institute$17,594,074
- Carolina Porras · Fundacion Inciensa$10,814,023
- Alanna Maguire · Mayo Clinic Rochester$9,942,431
- Hill Georgette · Integrated Laboratory Systems, Llc$8,700,000
Research focus
Malignant NeoplasmsClinical TrialsMonoclonal AntibodiesPlayTumor ImmunityCellsMacrophageAnti-Tumor Immune ResponseMyeloid CellsPhenotypeTissuesTumorImmuneNon-Small-Cell Lung CarcinomaMalignant Neoplasm Of LungCombined Modality TherapyImmunologic SurveillanceImmunosuppressionSignal TransductionCachexiaAlbuminsCancer CachexiaAdvanced DiseaseAnti-Pd1 Therapy
Grant awards (7)
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$1,263,739
R01 · FY2025 · CA
Clinical Trial Concept in the Oncology Landscape$314,877
R25 · FY2025 · CA
Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer$234,749
R21 · FY2025 · CA · contact PI
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$594,010
R01 · FY2024 · CA
Clinical Trial Concept in the Oncology Landscape$315,143
R25 · FY2024 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$615,393
R01 · FY2023 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$639,862
R01 · FY2022 · CA